The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Guillain‐Barré Syndrome following ChAdOx1‐S/nCoV‐19 Vaccine
Open accessAbstract
As of April 22, 2021, around 1.5 million individuals in three districts of Kerala, India had been vaccinated with COVID‐19 vaccines. Over 80% of these individuals (1.2 million) received the ChAdOx1‐S/nCoV‐19 vaccine. In this population, during this period of 4 weeks (mid‐March to mid‐April 2021), we observed seven cases of Guillain‐Barre syndrome (GBS) that occurred within 2 weeks of the first dose of vaccination. All seven patients developed severe GBS. The frequency of GBS was 1.4‐ to 10‐fold higher than that expected in this period for a population of this magnitude. In addition, the frequency of bilateral facial weakness, which typically occurs in <20% of GBS cases, suggests a pattern associated with the vaccination. While the benefits of vaccination substantially outweigh the risk of this relatively rare outcome (5.8 per million), clinicians should be alert to this possible adverse event, as six out of seven patients progressed to areflexic quadriplegia and required mechanical ventilatory support. ANN NEUROL 2021;90:312–314
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A method for estimating the probability of adverse drug reactions
Naranjo, C. A., Busto, U., Sellers, E. M., Sandor, P., Ruiz, I., Roberts, E. A., Janecek, E., Domecq, C., & Greenblatt, D. J. (1981) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1981.154 · Cited by 11,914 · cited 4×
“All seven patients developed severe GBS.”
BackgroundInfluentialThrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination
Greinacher, A., Thiele, T., Warkentin, T. E., Weisser, K., Kyrle, P. A., & Eichinger, S. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2104840 · Cited by 2,259 · cited 1×
“adenovector-based COVID-19 vaccines have recently been reported.(3) To date, one case of Guillain Barre Syndrome (GBS) has also been reported after Pfizer BNT-162b1 vaccination in the US.”
Cited by
New‐onset autoimmune phenomena post‐COVID‐19 vaccination
Chen, Y., Xu, Z., Wang, P., Li, X., Shuai, Z., Ye, D., & Pan, H. (2022) · Immunology · doi:10.1111/imm.13443 · Cited by 502
Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection
Patone, M., Handunnetthi, L., Saatci, D., Pan, J., Katikireddi, S. V., Razvi, S., Hunt, D., Mei, X. W., Dixon, S., Zaccardi, F., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01556-7 · Cited by 394
Incidence of Guillain-Barré syndrome after COVID-19 vaccination in the vaccine safety datalink
Hanson, K. E., Goddard, K., Lewis, N., Fireman, B., Myers, T. R., Bakshi, N., Weintraub, E., Donahue, J. G., Nelson, J. C., Xu, S., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.8879 · Cited by 160
Li, X., Raventós, B., Roel, E., Pistillo, A., Martinez-Hernandez, E., Delmestri, A., Reyes, C., Strauss, V., Prieto-Alhambra, D., Burn, E., et al. (2022) · BMJ · doi:10.1136/bmj-2021-068373 · Cited by 118
Frontera, J. A., Tamborska, A. A., Doheim, M. F., Garcia‐Azorin, D., Gezegen, H., Guekht, A., Yusof Khan, A. H. K., Santacatterina, M., Sejvar, J., Thakur, K. T., et al. (2022) · Annals of Neurology · doi:10.1002/ana.26339 · Cited by 108
“Other adenovirus vector COVID vaccines, such as ChAdOx1 (Oxford/AstraZeneca), have also been reported to generate higher than expected rates of GBS.25,26 We identified higher than expected rates of seizures following Janssen vaccination, which has not been previously reported.”
Background
Metadata
- Authors
- Maramattom, B. V., Krishnan, P., Paul, R., Padmanabhan, S., Cherukudal Vishnu Nampoothiri, S., Syed, A. A., & Mangat, H. S.
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2021-06-22
- Volume
- 90
- Issue
- 2
- Pages
- 312-314
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W3170053887
- Cited by
- 174
- References
- 2
- FWCI
- 17.31
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.